Idenix Pharmaceuticals Appoints Charles Rowland to Its Board of Directors
CAMBRIDGE, Mass., June 10, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals,
Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and
development of drugs for the treatment of human viral diseases, today
announced that it has appointed Charles Rowland to its Board of Directors. Mr.
Rowland is Vice President and Chief Financial Officer of ViroPharma
Incorporated. His appointment to Idenix's Board is effective immediately.
"Charlie brings valued financial expertise and background, with strong
experience implementing mid- and long-term strategic planning at innovative
biopharma companies," said Ron Renaud, President and Chief Executive Officer
of Idenix. "We are pleased to welcome Charlie to the Idenix Board at an
important time for the Company as it continues to advance all-oral combination
therapies for HCV, including a lead program in Phase II and earlier candidates
approaching the clinic."
Mr. Rowland has more than 28 years of diversified experience across a broad
field of financial areas and accounting, including financial reporting, tax,
treasury, and strategic financial planning. Prior to joining ViroPharma, he
was executive vice president and chief financial officer at Endo
Pharmaceuticals and served for a period as co-interim chief executive officer.
Previously, Mr. Rowland was senior vice president, chief financial officer
for Biovail Pharmacueticals. He also previously held positions of increasing
responsibility at Breakaway Technologies, Pharmacia, Novartis and
Bristol-Myers Squibb Company. Mr. Rowland holds a Bachelors of Science in
accounting from St. Joseph's University, and a Master of Business
Administration degree from the Rutgers University.
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a
biopharmaceutical Company engaged in the discovery and development of drugs
for the treatment of human viral diseases. Idenix's current focus is on the
treatment of patients with hepatitis C virus (HCV) infection. For further
information about Idenix, please refer to www.idenix.com.
CONTACT: Idenix Pharmaceuticals Contact:
Teri Dahlman, (617) 995-9807
Idenix Pharmaceuticals logo
Press spacebar to pause and continue. Press esc to stop.